Allergan's Rapid-Acting Antidepressant Fails in Key Studies

(Bloomberg) -- Allergan Plc shares fell after saying its fast-acting depression drug failed to show an improvement in symptoms beyond the placebo effect in three key studies.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.